Medicare proposes to limit coverage of Biogen Alzheimer’s drug
The program will only cover Aduhelm, which the FDA controversially approved last June, for patients enrolled in clinical trials.
The program will only cover Aduhelm, which the FDA controversially approved last June, for patients enrolled in clinical trials.